NCT05643534

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-11-15Est. Completion: 2026-09-01

Enrollment target: 180 participants

Locations

G & L Research, LLC, Foley, Alabama, United States
Eclipse Clinical Research, Tucson, Arizona, United States
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
Advanced Research Center, Inc., Anaheim, California, United States
Connecticut Children's Medical Center, Hartford, Connecticut, United States
Prohealth Research Center, Doral, Florida, United States
I.H.S. Health, LLC, Kissimmee, Florida, United States
Waterway Research & Associates Corp, Miami, Florida, United States
Valencia Medical and Research Center, Miami, Florida, United States
Orlando Health, Inc.- APH Center for Digestive Health and Nutrition, Orlando, Florida, United States
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
Clinical Research Institute, Stockbridge, Georgia, United States
OSF Saint Francis Medical Center, Peoria, Illinois, United States
Riley Children's Health IUH, Indianapolis, Indiana, United States
Maine Health, Portland, Maine, United States

Irritable Bowel Syndrome With Constipation (IBS-C)

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Foley, United StatesCompleted Jul 2031

Irritable Bowel Syndrome With Constipation (IBS-C)

This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor…

Little Rock, United StatesEst. completion Jul 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.